Aptabridge
Aptabridge Therapeutics is creating a next generation drug design platform to leverage DNA nanoparticles for immunotherapy. The company develops highly stable multi-specific molecules aimed at treating complex diseases by engaging two disease targets with one molecule. By using DNA nanoparticles instead of antibodies, Aptabridge aims to overcome challenges faced by bispecific antibodies, offering a product that is safer, lower cost, and easier to manufacture. Their modular design strategy allows for the mixing and matching of binding modules, making the platform versatile and scalable. The vision includes an AI-augmented system for direct clinical use, analyzing patient tissue for unique biomarkers and synthesizing therapeutic molecules in one device.
Aptabridge
Aptabridge Therapeutics is creating a next generation drug design platform to leverage DNA nanoparticles for immunotherapy. The company develops highly stable multi-specific molecules aimed at treating complex diseases by engaging two disease targets with one molecule. By using DNA nanoparticles instead of antibodies, Aptabridge aims to overcome challenges faced by bispecific antibodies, offering a product that is safer, lower cost, and easier to manufacture. Their modular design strategy allows for the mixing and matching of binding modules, making the platform versatile and scalable. The vision includes an AI-augmented system for direct clinical use, analyzing patient tissue for unique biomarkers and synthesizing therapeutic molecules in one device.